NxStage Medical CEO Sells $70,000 in Stock (NXTM)
NxStage Medical (NASDAQ:NXTM) CEO Jeffrey H. Burbank sold 5,000 shares of NxStage Medical stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $14.00, for a total value of $70,000.00. Following the completion of the transaction, the chief executive officer now directly owns 641,711 shares of the company’s stock, valued at approximately $8,983,954. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of NxStage Medical (NASDAQ:NXTM) traded down 0.71% on Monday, hitting $13.96. The stock had a trading volume of 214,224 shares. NxStage Medical has a 52 week low of $8.77 and a 52 week high of $15.00. The stock has a 50-day moving average of $12.69 and a 200-day moving average of $12.25. The company’s market cap is $857.4 million.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. On average, analysts predict that NxStage Medical will post $-0.40 earnings per share for the current fiscal year.
NXTM has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. Analysts at Wells Fargo & Co. downgraded shares of NxStage Medical from a “market perform” rating to an “underperform” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $16.83.
NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.